Table 1.
Patient No. | Age, y/Sex | Cancer Diagnosis | Clinical History | I/O Medication | Time to First Symptoms, da | Outcome |
---|---|---|---|---|---|---|
| ||||||
1 | 53/F | Lymphoma | DM, hypertension, dyslipidemia | Atezolizumab | 19 | Resolution, 17 d |
2 | 70/M | Hepatocellular | DM | Pembrolizumab | 6 | Resolution, 2 mo |
3 | 75/F | Endometrial carcinoma | No significant history | Tremelimumab, durvalumab | 21 | Resolution, 14 d |
4 | 71/M | Melanoma | No significant history | Nivolumab, ipilimumab | 7 | Death (heart failure, multisystem organ failure) |
5 | 75/M | Pancreatic carcinoma | DM, hypertension, dyslipidemia | Nivolumab | 38 | Resolution (partial), 20 d |
6 | 83/F | Melanoma | Hypothyroidism, hypertension, dyslipidemia, COPD | Nivolumab | 21 | Resolution, 7 d |
Abbreviations: COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; I/O, immune oncology.
After last dose of immune-oncology agent.